Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Jun;479(6):1319-1333.
doi: 10.1007/s11010-023-04798-w. Epub 2023 Jul 4.

Potential in exosome-based targeted nano-drugs and delivery vehicles for posterior ocular disease treatment: from barriers to therapeutic application

Affiliations
Review

Potential in exosome-based targeted nano-drugs and delivery vehicles for posterior ocular disease treatment: from barriers to therapeutic application

Xingru Peng et al. Mol Cell Biochem. 2024 Jun.

Abstract

Posterior ocular disease, a disease that accounts for 55% of all ocular diseases, can contribute to permanent vision loss if left without treatment. Due to the special structure of the eye, various obstacles make it difficult for drugs to reach lesions in the posterior ocular segment. Therefore, the development of highly permeable targeted drugs and delivery systems is particularly important. Exosomes are a class of extracellular vesicles at 30-150 nm, which are secreted by various cells, tissues, and body fluids. They carry various signaling molecules, thus endowing them with certain physiological functions. In this review, we describe the ocular barriers and the biogenesis, isolation, and engineering of exosomes, as exosomes not only have pharmacological effects but also are good nanocarriers with targeted properties. Moreover, their biocompatibility and immunogenicity are better than synthetic nanocarriers. Most importantly, they may have the ability to pass through the blood-eye barrier. Thus, they may be developed as both targeted nano-drugs and nano-delivery vehicles for the treatment of posterior ocular diseases. We focus on the current status and potential application of exosomes as targeted nano-drugs and nano-delivery vehicles in posterior ocular diseases.

Keywords: Exosome; Posterior ocular disease; Targeted nano-delivery vehicles; Targeted nano-drugs.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Juliana FR, Kesse S, Boakye-Yiadom KO, Veroniaina H, Wang HH, Sun MH (2019) Promising approach in the treatment of glaucoma using nanotechnology and nanomedicine-based systems. Molecules. https://doi.org/10.3390/molecules24203805 - DOI - PubMed - PMC
    1. Joseph RR, Venkatraman SS (2017) Drug delivery to the eye: what benefits do nanocarriers offer? Nanomedicine 12:683–702. https://doi.org/10.2217/nnm-2016-0379 - DOI - PubMed
    1. Nayak K, Misra M (2018) A review on recent drug delivery systems for posterior segment of eye. Biomed Pharmacother 107:1564–1582. https://doi.org/10.1016/j.biopha.2018.08.138 - DOI - PubMed
    1. Wang R, Gao Y, Liu AC, Zhai GX (2021) A review of nanocarrier-mediated drug delivery systems for posterior segment eye disease: challenges analysis and recent advances. J Drug Target 29:687–702. https://doi.org/10.1080/1061186x.2021.1878366 - DOI - PubMed
    1. Naidorf-Rosenblatt H, Landau-Part D, Moisseiev J, Alhalel A, Huna-Baron R, Skaat A, Pilus S, Levi L, Leshno A (2022) Ocular surface temperature differences in retinal vascular diseases. Retina-J Retinal Vitreous Dis 42:152–158. https://doi.org/10.1097/IAE.0000000000003278 - DOI